https://www.fool.com/investing/dividends-income/2008/06/11/dueling-fools-pfizer-bear.aspx
https://www.fool.com/investing/high-growth/2008/08/12/the-fda-stands-up-cardiome.aspx
https://www.fool.com/investing/high-growth/2008/09/30/a-top-biomarin-drug-heads-overseas.aspx
https://www.fool.com/investing/high-growth/2008/06/05/vertex-cashes-in.aspx
https://www.fool.com/investing/high-growth/2008/06/27/this-drug-market-is-booming.aspx
https://www.fool.com/investing/high-growth/2008/06/11/pain-and-king-start-the-countdown.aspx
https://www.fool.com/investing/high-growth/2008/09/26/intermune-previews-a-coming-attraction.aspx
https://www.fool.com/investing/high-growth/2008/07/09/viropharma-makes-its-case.aspx
https://www.fool.com/investing/small-cap/2008/08/13/dilution-lurks-at-aob.aspx
https://www.fool.com/investing/high-growth/2008/06/27/difficult-obstacles-for-sciclone.aspx
https://www.fool.com/investing/high-growth/2008/08/01/holy-moley-cv-therapeutics.aspx
https://www.fool.com/investing/dividends-income/2008/09/30/no-approval-for-you-yet.aspx
https://www.fool.com/investing/high-growth/2008/07/03/a-cubist-masterstroke.aspx
https://www.fool.com/investing/high-growth/2008/06/09/novo-nordisks-daring-success.aspx
https://www.fool.com/investing/high-growth/2008/06/25/why-the-lilly-delay-fda.aspx
https://www.fool.com/investing/high-growth/2008/08/06/exelixis-gets-ready-to-partner-up.aspx
https://www.fool.com/investing/high-growth/2008/07/25/glaxo-changes-course.aspx
https://www.fool.com/investing/high-growth/2008/08/01/elan-becomes-a-bad-news-buy.aspx
https://www.fool.com/investing/high-growth/2008/08/21/pdl-biopharmas-partnership-makes-sense.aspx
https://www.fool.com/investing/high-growth/2008/07/01/myriads-small-billion-dollar-loss.aspx
https://www.fool.com/investing/high-growth/2008/07/02/durects-intriguing-little-orphan.aspx
https://www.fool.com/investing/high-growth/2008/07/08/blockbuster-drugs-bound-for-extinction.aspx
https://www.fool.com/investing/general/2008/09/11/imclone-may-not-be-done-with-bristol-myers.aspx
https://www.fool.com/investing/dividends-income/2008/06/26/gauging-glaxos-vaccine-value.aspx
https://www.fool.com/investing/high-growth/2008/08/04/vertex-on-the-verge-of-victory.aspx
https://www.fool.com/investing/high-growth/2008/07/28/amgens-bone-building-boost.aspx
https://www.fool.com/investing/high-growth/2008/09/24/one-share-offering-too-many-for-vertex.aspx
https://www.fool.com/investing/general/2008/09/05/why-pfizer-made-an-interesting-blockbuster-bet.aspx
https://www.fool.com/investing/general/2008/09/04/sitting-tight-in-september.aspx
https://www.fool.com/investing/high-growth/2008/07/16/a-big-move-from-viropharma.aspx
https://www.fool.com/investing/general/2008/09/12/a-new-wrinkle-for-an-old-drug.aspx
https://www.fool.com/investing/general/2008/09/19/fda-tells-gilead-to-take-1-more-step.aspx
https://www.fool.com/investing/value/2008/09/16/pfizer-puts-safety-first.aspx
https://www.fool.com/investing/high-growth/2008/08/14/a-potentially-painless-pdufa-date.aspx
https://www.fool.com/investing/high-growth/2008/07/10/lilly-targets-a-tiny-prize.aspx
https://www.fool.com/investing/value/2008/07/24/will-pfizer-pfizzle.aspx
https://www.fool.com/investing/high-growth/2008/08/06/biomarins-new-drugs-mostly-hit-their-targets.aspx
https://www.fool.com/investing/high-growth/2008/09/23/will-generic-biologics-get-special-treatment.aspx
https://www.fool.com/investing/high-growth/2008/06/18/elans-and-wyeths-data-success-or-failure.aspx
https://www.fool.com/investing/dividends-income/2008/09/10/a-pfizer-drug-with-a-cloudy-future.aspx
https://www.fool.com/investing/high-growth/2008/06/12/gileads-got-the-goods.aspx
https://www.fool.com/investing/high-growth/2008/07/18/still-liking-gilead-warts-and-all.aspx
https://www.fool.com/investing/high-growth/2008/08/25/amgen-gets-its-fda-response.aspx
https://www.fool.com/investing/high-growth/2008/07/03/celgene-savors-the-schadenfreude.aspx
https://www.fool.com/investing/high-growth/2008/06/10/vertex-doesnt-disappoint.aspx
https://www.fool.com/investing/general/2008/08/11/not-bad-novo-nordisk.aspx
https://www.fool.com/investing/general/2008/09/24/sanofi-gets-the-golden-ring.aspx
https://www.fool.com/investing/high-growth/2008/08/28/cell-genesys-takes-a-body-blow.aspx
https://www.fool.com/investing/high-growth/2008/06/13/gsk-gears-up-a-blockbuster.aspx
https://www.fool.com/investing/high-growth/2008/09/26/less-is-more-for-vertex.aspx
https://www.fool.com/investing/high-growth/2008/07/10/seattle-genetics-gets-some-platform-love.aspx
https://www.fool.com/investing/general/2008/09/24/bristol-myers-puts-icahn-and-imclone-to-the-test.aspx
https://www.fool.com/investing/high-growth/2008/07/02/a-hearteningly-cheap-rule-breaker.aspx
https://www.fool.com/investing/high-growth/2008/06/27/more-cash-for-cvt.aspx
https://www.fool.com/investing/dividends-income/2008/07/01/glaxosmithkline-gets-fda.aspx
https://www.fool.com/investing/high-growth/2008/06/26/ardea-takes-the-more-exciting-route.aspx
https://www.fool.com/investing/high-growth/2008/08/14/genentech-asks-roche-to-pay-up.aspx
https://www.fool.com/investing/general/2008/09/22/why-bristol-myers-wont-pull-its-imclone-bid.aspx
https://www.fool.com/investing/high-growth/2008/09/12/kings-unstoppable-urge-to-merge.aspx
https://www.fool.com/investing/high-growth/2008/06/06/sorry-sanofi-more-bad-news.aspx
https://www.fool.com/investing/general/2008/08/25/king-triples-down.aspx
https://www.fool.com/investing/general/2008/06/11/he-said-biogen-said.aspx
https://www.fool.com/investing/general/2008/08/05/an-imclone-deal-will-get-done.aspx
https://www.fool.com/investing/high-growth/2008/06/13/novo-nordisk-bleeds-a-little.aspx
https://www.fool.com/investing/high-growth/2008/06/17/exelixis-gets-special-treatment.aspx
https://www.fool.com/investing/high-growth/2008/07/22/anxiously-awaiting-exelixis.aspx
https://www.fool.com/investing/high-growth/2008/09/17/cv-therapeutics-expands-ranexas-reach.aspx
https://www.fool.com/investing/high-growth/2008/06/23/wait-a-little-longer-ligand.aspx
https://www.fool.com/investing/high-growth/2008/06/05/cancer-concerns-fuel-fda-inquiry.aspx
https://www.fool.com/investing/high-growth/2008/07/15/genentech-needs-more-profit-power.aspx
https://www.fool.com/investing/general/2008/06/13/lilly-patches-its-pipeline.aspx
https://www.fool.com/investing/high-growth/2008/07/01/exelixis-and-glaxo-begin-their-goodbyes.aspx
https://www.fool.com/investing/high-growth/2008/08/18/when-breaking-up-isnt-hard-to-do.aspx
https://www.fool.com/investing/high-growth/2008/08/29/will-biopharma-acquisitions-never-cease.aspx
https://www.fool.com/investing/dividends-income/2008/06/19/pfizers-small-lipitor-win.aspx
https://www.fool.com/investing/high-growth/2008/07/09/predicting-more-good-news-from-invitrogen.aspx
https://www.fool.com/investing/high-growth/2008/08/20/telaprevir-tests-its-luck.aspx
https://www.fool.com/investing/high-growth/2008/06/27/drugmakers-not-so-recession-proof.aspx
https://www.fool.com/investing/general/2008/08/26/fda-changes-course-for-elan-and-biogen-idec.aspx
https://www.fool.com/investing/general/2008/07/31/examining-elans-ups-and-downs.aspx
https://www.fool.com/investing/small-cap/2008/06/10/buy-back-shares-then-issue-more.aspx
https://www.fool.com/investing/general/2008/06/23/sanofi-goes-east-to-find-growth.aspx
https://www.fool.com/investing/general/2008/09/11/will-a-change-cure-sanofi.aspx
https://www.fool.com/investing/high-growth/2008/08/01/is-60-a-share-enough-for-imclone.aspx
https://www.fool.com/investing/dividends-income/2008/09/30/novo-nordisk-takes-on-all-comers.aspx
https://www.fool.com/investing/general/2008/07/23/no-picking-at-biogen.aspx
https://www.fool.com/investing/general/2008/07/25/place-your-biotech-bets.aspx
https://www.fool.com/investing/small-cap/2008/08/25/be-careful-with-pay-for-analyst-research.aspx
https://www.fool.com/investing/small-cap/2008/09/18/busy-day-for-mannkind.aspx
https://www.fool.com/investing/high-growth/2008/06/06/nothing-can-stop-novartis.aspx
https://www.fool.com/investing/high-growth/2008/06/10/allergans-unblemished-deal.aspx
https://www.fool.com/investing/high-growth/2008/07/21/amgen-rolls-the-dice.aspx
https://www.fool.com/investing/high-growth/2008/06/27/vandas-drug-draws-a-yawn.aspx
https://www.fool.com/investing/small-cap/2008/08/08/flamel-still-trying-to-pull-off-a-turnaround.aspx
https://www.fool.com/investing/high-growth/2008/09/30/moodys-gets-moody-with-drugmakers.aspx
https://www.fool.com/investing/general/2008/09/25/another-win-for-disclosure.aspx
https://www.fool.com/investing/high-growth/2008/06/24/barrier-taken-down.aspx
https://www.fool.com/investing/high-growth/2008/06/10/exelixis-secures-its-future.aspx
https://www.fool.com/investing/high-growth/2008/07/21/roche-wants-to-buy-genentech-again.aspx
https://www.fool.com/investing/high-growth/2008/08/21/regenerons-results-clearing-up.aspx
